Photo: Ruselectronics
Ruselectronics holding has developed an autoimmune disease treatment device that is unparalleled in domestic medicine. Such devices have been supplied earlier only from abroad. Kit-A – an ultraviolet blood mononuclear cell irradiator that, unlike traditional chemotherapy, does not affect normal organs and tissues and can provide stable remission for several years. The device has already received a certificate of registration issued by the Federal Service for Supervision in Healthcare.
The UV irradiator developed by RPC Tsiklon-Test included in Ruselectronics uses the extracorporeal photoradiation therapy (photopheresis) technique. Patient’s blood is removed and plasma with mononuclear cells is isolated from it, then the mononuclear cells are exposed to 365 nm UV irradiation. This results in death of malignant T-cells. Then the cell-rich fluid is returned to the patient’s blood. UV irradiation allows stable remission to be achieved for several years and, unlike traditional chemotherapy, does not affect normal organs and tissues.
“Medical device industry – is one of Rostec’s business priorities. Our major holding companies are working on the development of products capable of surpassing and replacing foreign counterparts. The Kit-A is the first Russian ultraviolet blood mononuclear cell irradiator. It can be used not only for treatment of acquired immunity diseases, but also for rehabilitation after transplantation. The domestic device will be several times cheaper than its foreign counterparts,” said Rostec’s representatives.
